OncoMatch

OncoMatch/Clinical Trials/NCT07478731

Neoadjuvant SHR-1701 Plus Chemoradiotherapy for Locally Advanced Rectal Cancer

Is NCT07478731 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies SHR-1701 neoadjuvant for crc (colorectal cancer).

Phase 2RecruitingHong QiuNCT07478731Data as of May 2026

Treatment: SHR-1701 neoadjuvantThe goal of this clinical trial is to learn if SHR-1701 combine with chemoradiotherapy works to treat severe CRC. Participants will take: Induction: SHR-1701 combined with CAPOX for one cycle. Radiotherapy: Short-course radiotherapy (SCRT) (25Gy/5F). Consolidation: SHR-1701 combined with CAPOX for five cycles, after which the subjects undergo TME surgery.

Check if I qualify

Extracted eligibility criteria

Cancer type

Colorectal Cancer

Biomarker criteria

Required: MMR proficient

pMMR or MSS/MSI-L rectal adenocarcinoma

Required: MSI microsatellite stable

pMMR or MSS/MSI-L rectal adenocarcinoma

Required: MSI MSI-L

pMMR or MSS/MSI-L rectal adenocarcinoma

Disease stage

Required: Stage CN2 (clinical TNM)

At least meet any of the following criteria:cT3-4、cN2、EMVI+、MRF+

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

No prior treatment (treatment-naive required)
Max 0 prior lines

Cannot have received: surgery

Patients has not received any anti-tumor treatment before, including surgery, radiotherapy, chemotherapy, targeting therapy and immunotherapy

Cannot have received: radiotherapy

Patients has not received any anti-tumor treatment before, including surgery, radiotherapy, chemotherapy, targeting therapy and immunotherapy

Cannot have received: chemotherapy

Patients has not received any anti-tumor treatment before, including surgery, radiotherapy, chemotherapy, targeting therapy and immunotherapy

Cannot have received: targeted therapy

Patients has not received any anti-tumor treatment before, including surgery, radiotherapy, chemotherapy, targeting therapy and immunotherapy

Cannot have received: immunotherapy

Patients has not received any anti-tumor treatment before, including surgery, radiotherapy, chemotherapy, targeting therapy and immunotherapy

Lab requirements

Blood counts

Main organ function efficient, including blood routine examination, blood biochemical examination, coagulation function

Kidney function

Main organ function efficient, including blood routine examination, blood biochemical examination, coagulation function

Liver function

Main organ function efficient, including blood routine examination, blood biochemical examination, coagulation function

Main organ function efficient, including blood routine examination, blood biochemical examination, coagulation function

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify